194 related articles for article (PubMed ID: 32757330)
1. Oncogenic mutations within the β3-αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies.
Zhang B; Chen Y; Dai P; Yu H; Ma J; Chen C; Zhang Y; Guan Y; Chen R; Liu T; Wang J; Yang L; Yi X; Xia X; Ma H
Mol Genet Genomic Med; 2020 Oct; 8(10):e1395. PubMed ID: 32757330
[TBL] [Abstract][Full Text] [Related]
2. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.
Foster SA; Whalen DM; Özen A; Wongchenko MJ; Yin J; Yen I; Schaefer G; Mayfield JD; Chmielecki J; Stephens PJ; Albacker LA; Yan Y; Song K; Hatzivassiliou G; Eigenbrot C; Yu C; Shaw AS; Manning G; Skelton NJ; Hymowitz SG; Malek S
Cancer Cell; 2016 Apr; 29(4):477-493. PubMed ID: 26996308
[TBL] [Abstract][Full Text] [Related]
3. MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
Chuang J; Wang C; Guo Y; Valenzuela V; Wu J; Fakih M
Clin Colorectal Cancer; 2021 Mar; 20(1):72-78. PubMed ID: 33436306
[TBL] [Abstract][Full Text] [Related]
4. Resistance mechanism of the oncogenic β3-αC deletion mutation in BRAF kinase to dabrafenib and vemurafenib revealed by molecular dynamics simulations and binding free energy calculations.
Niu Y; Zhang Y; Yao X
Chem Biol Drug Des; 2019 Feb; 93(2):177-187. PubMed ID: 30225883
[TBL] [Abstract][Full Text] [Related]
5. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
Chen SH; Zhang Y; Van Horn RD; Yin T; Buchanan S; Yadav V; Mochalkin I; Wong SS; Yue YG; Huber L; Conti I; Henry JR; Starling JJ; Plowman GD; Peng SB
Cancer Discov; 2016 Mar; 6(3):300-15. PubMed ID: 26732095
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
[TBL] [Abstract][Full Text] [Related]
8. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
10. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
Hechtman JF; Zehir A; Yaeger R; Wang L; Middha S; Zheng T; Hyman DM; Solit D; Arcila ME; Borsu L; Shia J; Vakiani E; Saltz L; Ladanyi M
Mol Cancer Res; 2016 Mar; 14(3):296-301. PubMed ID: 26660078
[TBL] [Abstract][Full Text] [Related]
11. High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.
Mizuno S; Ikegami M; Koyama T; Sunami K; Ogata D; Kage H; Yanagaki M; Ikeuchi H; Ueno T; Tanikawa M; Oda K; Osuga Y; Mano H; Kohsaka S
Mol Cancer Ther; 2023 Feb; 22(2):227-239. PubMed ID: 36442478
[TBL] [Abstract][Full Text] [Related]
12. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.
Chakraborty R; Burke TM; Hampton OA; Zinn DJ; Lim KP; Abhyankar H; Scull B; Kumar V; Kakkar N; Wheeler DA; Roy A; Poulikakos PI; Merad M; McClain KL; Parsons DW; Allen CE
Blood; 2016 Nov; 128(21):2533-2537. PubMed ID: 27729324
[TBL] [Abstract][Full Text] [Related]
13. Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma.
Xiang C; Ji C; Cai Y; Teng H; Wang Y; Zhao R; Shang Z; Guo L; Chen S; Lizaso A; Lin J; Wang H; Li B; Zhang Z; Zhao J; Wei J; Liu J; Zhu L; Fang W; Han Y
Mod Pathol; 2022 Sep; 35(9):1181-1192. PubMed ID: 35641658
[TBL] [Abstract][Full Text] [Related]
14. Altered conformational landscape and dimerization dependency underpins the activation of EGFR by
Ruan Z; Kannan N
Proc Natl Acad Sci U S A; 2018 Aug; 115(35):E8162-E8171. PubMed ID: 30104348
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
[TBL] [Abstract][Full Text] [Related]
16. An amino-terminal
Tung JK; Neishaboori N; Haraldsdottir S; Suarez CJ
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32669268
[TBL] [Abstract][Full Text] [Related]
17. Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism.
Fan YX; Wong L; Ding J; Spiridonov NA; Johnson RC; Johnson GR
J Biol Chem; 2008 Jan; 283(3):1588-1596. PubMed ID: 18039657
[TBL] [Abstract][Full Text] [Related]
18. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
[TBL] [Abstract][Full Text] [Related]
19. High frequency of BRAF V600E mutations in ameloblastoma.
Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
[TBL] [Abstract][Full Text] [Related]
20. Deja Vu: EGF receptors drive resistance to BRAF inhibitors.
Girotti MR; Marais R
Cancer Discov; 2013 May; 3(5):487-90. PubMed ID: 23658295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
